Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Receivables: 2019-2025

Historic Receivables for Catalyst Pharmaceuticals (CPRX) over the last 7 years, with Sep 2025 value amounting to $106.4 million.

  • Catalyst Pharmaceuticals' Receivables rose 82.63% to $106.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $309.0 million, marking a year-over-year increase of 34.68%. This contributed to the annual value of $65.5 million for FY2024, which is 22.35% up from last year.
  • According to the latest figures from Q3 2025, Catalyst Pharmaceuticals' Receivables is $106.4 million, which was up 61.56% from $65.9 million recorded in Q2 2025.
  • In the past 5 years, Catalyst Pharmaceuticals' Receivables ranged from a high of $106.4 million in Q3 2025 and a low of $5.6 million during Q1 2021.
  • For the 3-year period, Catalyst Pharmaceuticals' Receivables averaged around $60.2 million, with its median value being $58.3 million (2024).
  • Per our database at Business Quant, Catalyst Pharmaceuticals' Receivables declined by 19.04% in 2021 and then soared by 414.61% in 2023.
  • Quarterly analysis of 5 years shows Catalyst Pharmaceuticals' Receivables stood at $6.6 million in 2021, then spiked by 57.71% to $10.4 million in 2022, then surged by 412.64% to $53.5 million in 2023, then rose by 22.35% to $65.5 million in 2024, then spiked by 82.63% to $106.4 million in 2025.
  • Its last three reported values are $106.4 million in Q3 2025, $65.9 million for Q2 2025, and $71.3 million during Q1 2025.